Mebendazole Cracks Gefitinib Resistance in Lung Cancer — Combo Slowed Tumors Fourfold in Mice
In gefitinib-resistant lung cancer cells, adding mebendazole cut surviving cells from 92.7% to 37.7%; in mice, tumor doubling time stretched from 6.2 to 25 days.
By Sanare Lab · October 9, 2026 · 2 min read
Key Takeaway
Some lung cancers stop responding to gefitinib, a targeted drug. Adding mebendazole — a cheap deworming pill — restored the drug's punch in resistant cells and in mice: tumors grew about four times slower. Preclinical work (cells and mice), not yet tested in patients.
In EGFR-mutant non-small cell lung cancer (NSCLC — the commonest lung cancer type, driven here by a stuck 'grow' switch called EGFR), acquired resistance to EGFR drugs is a major wall. Researchers asked whether mebendazole, a microtubule disruptor (it breaks the tiny scaffolding tubes cells need to divide), could re-sensitize gefitinib-resistant HCC827 GR5 cells.
Gefitinib alone barely worked: 92.7% of resistant cells stayed alive. Mebendazole alone left 79.7% alive at 0.1 µM and 29.7% at 0.5 µM (µM = micromolar, a small lab concentration). The combination left just 37.7% alive (p<0.001 — unlikely to be chance). The combo inflicted replication stress — damage that builds up when cells copy their DNA: comet assays (gel tests that visualize broken DNA) showed 22.33% tail intensity, with dose-dependent γ-H2AX activation, a molecular alarm for DNA breaks.
In mice, the combination stretched tumor doubling time from 6.2 to 25 days — roughly four times slower — with a growth delay of 18.8 days (p<0.01) and no substantial systemic toxicity. See earlier mebendazole lung-cancer work and our fenbendazole vs mebendazole comparison; dosing: our dosing calculator.
In plain words
What happened: Researchers added mebendazole, a cheap deworming pill, to the lung-cancer drug gefitinib — in lab cells and in mice whose tumors no longer responded to gefitinib alone.
Why it matters: Lung tumors often learn to ignore gefitinib. Mebendazole breaks the scaffolding cancer cells need to divide, causing DNA damage — and that seems to make the tumor vulnerable to the drug again.
How strong is the evidence: Early but real data: cancer cells in dishes plus mice. Mouse tumors grew four times slower with no major side effects seen — but no patients have been treated.
What it means for you: Nothing changes for patients yet; this is not a proven treatment. Do not self-experiment — any off-label use belongs with your oncology team.
References
- El-Tanani M, Satyam SM, Prabhakar S, et al. Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer. PLoS One. 2026 Oct 8. doi:10.1371/journal.pone.0360164. PMID: 42848765.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The study was done in cancer cells and mice, not in patients. Never start, stop or change any medication or supplement without consulting your doctor.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.